[(CXCR4,overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,breast cancer,0.9394228952478257), (CXCR4,overexpressed in,breast cancer,0.9394228952478257)][(CXCR4,overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,breast cancer,0.9394228952478257), (CXCR4,overexpressed in,breast cancer,0.9394228952478257)][(CXCR4,overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,breast cancer,0.9394228952478257), (CXCR4,overexpressed in,breast cancer,0.9394228952478257)][(CXCR4,overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,invasive breast cancer,0.9394228952478257), (CXCR4,frequently overexpressed in,breast cancer,0.9394228952478257), (CXCR4,overexpressed in,breast cancer,0.9394228952478257)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(patients,is with,breast cancer,1.0), (aim,assess,diagnostic performance in patients,1.0), (aim,assess,performance in patients,1.0), (performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging,1.0), (aim,assess,performance of PET imaging in patients with breast cancer,1.0), (performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance,1.0), (diagnostic performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance of PET imaging in patients,1.0), (aim,assess,diagnostic performance of CXCR4-directed PET imaging in patients,1.0), (aim,assess,performance of PET imaging,1.0), (performance,using,introduced PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging,1.0), (aim,assess,diagnostic performance of PET imaging in patients,1.0), (aim,assess,performance of CXCR4-directed PET imaging,1.0), (aim,assess,diagnostic performance,1.0), (diagnostic performance,using,CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,using,PET probe 68Ga-Pentixafor,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients,1.0), (diagnostic performance,using,recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance in patients with breast cancer,1.0), (diagnostic performance,using,recently introduced PET probe 68Ga-Pentixafor,1.0), (aim,assess,diagnostic performance of PET imaging in patients with breast cancer,1.0), (aim,assess,performance of CXCR4-directed PET imaging in patients with breast cancer,1.0), (aim,assess,performance in patients with breast cancer,1.0), (performance,using,PET probe 68Ga-Pentixafor,1.0), (diagnostic performance,is in,patients with breast cancer,1.0)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (four patients,is with,recurrent disease,1.0), (CXCR4-targeted PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709), (CXCR4-targeted PET imaging,patients with,first diagnosis of breast cancer,0.864372018453727), (CXCR4-targeted PET imaging,using,68Ga-Pentixafor,1.0), (Thirteen patients,patient with,axillary lymph node metastasis of unknown primary,0.24458331851216994), (one patient,is with,axillary lymph node metastasis of unknown primary,1.0), (PET imaging,using,68Ga-Pentixafor,1.0), (PET imaging,patient with,axillary lymph node metastasis of unknown primary,0.9352972027689709)][(tumor-to-background ratios,were,measured,1.0)][(18F-FDG PET/CT images,were available in,8/18 cases,1.0), (18F-FDG PET/CT images,were,available,1.0), (18F-FDG PET/CT images,were,compared,1.0), (18F-FDG PET/CT images,were,compared semi-quantitatively,1.0)][(18F-FDG PET/CT images,were available in,8/18 cases,1.0), (18F-FDG PET/CT images,were,available,1.0), (18F-FDG PET/CT images,were,compared,1.0), (18F-FDG PET/CT images,were,compared semi-quantitatively,1.0)][(18F-FDG PET/CT images,were available in,8/18 cases,1.0), (18F-FDG PET/CT images,were,available,1.0), (18F-FDG PET/CT images,were,compared,1.0), (18F-FDG PET/CT images,were,compared semi-quantitatively,1.0)][(18F-FDG PET/CT images,were available in,8/18 cases,1.0), (18F-FDG PET/CT images,were,available,1.0), (18F-FDG PET/CT images,were,compared,1.0), (18F-FDG PET/CT images,were,compared semi-quantitatively,1.0)][(Comparison,was performed in,7/18 patients,1.0), (Comparison,is with,CXCR4 expression determined by immunohistochemistry,1.0), (Comparison,was,performed,1.0)][(Comparison,was performed in,7/18 patients,1.0), (Comparison,is with,CXCR4 expression determined by immunohistochemistry,1.0), (Comparison,was,performed,1.0)][(Comparison,was performed in,7/18 patients,1.0), (Comparison,is with,CXCR4 expression determined by immunohistochemistry,1.0), (Comparison,was,performed,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(Metastases,were,visually detectable,1.0), (Metastases,exhibiting,SUVmax of 3.5,1.0), (Metastases,exhibiting,mean SUVmax of 3.5,1.0), (Metastases,were visually detectable in,all five cases,1.0), (Metastases,were,detectable,1.0), (Metastases,exhibiting,SUVmax,1.0), (exhibiting,SUVmax of,3.5,0.5425682436898807), (exhibiting,mean SUVmax of,3.5,0.5425682436898807), (Metastases,exhibiting,mean SUVmax,1.0), (Metastases,were detectable in,all five cases,1.0)][(higher SUVmax,is in,patients,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(tumor detectability,is significantly lower compared to,18F-FDG PET,1.0), (tumor detectability,is,however lower,1.0), (tumor detectability,is,however significantly lower,1.0), (tumor detectability,however is significantly lower compared to,18F-FDG PET,1.0), (CXCR4-directed PET imaging,is in,patients with primary breast cancer,1.0), (patients,is with,primary breast cancer,1.0), (tumor detectability,is,lower,1.0), (tumor detectability,is,significantly lower,1.0), (tumor detectability,however is lower compared to,18F-FDG PET,1.0), (tumor detectability,is lower compared to,18F-FDG PET,1.0)][(results,is in,small patient cohort,1.0)][(current developments,is in,targeted immune cell,1.0), (more specific applications,is in,therapeutic approaches especially under view of current developments,1.0)][(current developments,is in,targeted immune cell,1.0), (more specific applications,is in,therapeutic approaches especially under view of current developments,1.0)]